---
figid: PMC8886863__40487_2022_187_Fig1_HTML
pmcid: PMC8886863
image_filename: 40487_2022_187_Fig1_HTML.jpg
figure_link: /pmc/articles/PMC8886863/figure/Fig1/
number: Fig. 1
figure_title: ''
caption: Expected durations of regulatory and HTA reviews of oncology drugs in Canada
  and some reference countries. Estimated durations assume no regulatory delays. TGA,
  Therapeutic Goods Administration [–]; PBAC, Pharmaceutical Benefits Advisory Committee
  [, ]; HC, Health Canada []; CADTH, Canadian Agency for Drugs and Technologies in
  Health []; pCODR, pan-Canadian Oncology Drug Review [], INESSS, Institut National
  d’Excellence en Santé et en Services Sociaux []; NICE, National Institute for Health
  and Care Excellence []; EMA/CHMP, European Medicines Agency/Committee for Medicinal
  Products for Human Use [–]; HAS, Haute Autorité de Santé [–]; G-BA, Gemeinsamer
  Bundesausschuss []; AIFA, Agenzia Italiana del Farmaco [, ]; ZiN, Zorginstituut
  Nederland [, ]; CAMHDA, Advisory Board of Hospital Medication Dispensed to Outpatients
  [, ]; GENESIS, Group for Innovation, Assessment, Standardization and Research in
  the Selection of Drugs [, ]; and GFTHA, Andalusian Hospital Formulary guideline
  [, ]. Market access in Germany and the Netherlands may also be attained via the
  centralized EMA/CHMP pathway. HTA health technology assessment
article_title: Estimating the Impact of Delayed Access to Oncology Drugs on Patient
  Outcomes in Canada.
citation: Jackie Vanderpuye-Orgle, et al. Oncol Ther. 2022 Jun;10(1):195-210.
year: '2022'

doi: 10.1007/s40487-022-00187-3
journal_title: Oncology and Therapy
journal_nlm_ta: Oncol Ther
publisher_name: Springer Healthcare

keywords:
- NSCLC
- Targeted therapies
- HTA
- CADTH
- Reimbursement
- Canada
- Patient access
- QALY
- Quality of life

---
